Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nightstar Therapeutics plcNITE · Entity 156809 | Director | June 07, 2019 | June 07, 2019 |
| PROTHENA CORP PUBLIC LTD COPRTA · Entity 2375 | Director | May 14, 2025 | May 16, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nightstar Therapeutics plc
Report date June 07, 2019 · Filed June 07, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.16 · Expires 2028-09-11 | Direct | 0 |
Reported balance
After 2019-06-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-07 · Disposition to issuer · Disposed 36,400 · Balance 0 F3: Represents the payment per share received in exchange for the cancellation of each option of $25.50, less the applicable exercise price. F1: In connection with the acquisition by Tungsten Bidco Limited of the entire issued and to be issued share capital of Nightstar Therapeutics plc (the "Issuer") on June 7, 2019 by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006, all stock options were cancelled in exchange for a payment equal to $25.50 with respect to each ordinary share subject to the option award, less the applicable exercise price. F2: The ordinary shares, nominal value GBP 0.01 per share, of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.57 · Expires 2029-01-24 | Direct | 0 |
Reported balance
After 2019-06-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-06-07 · Disposition to issuer · Disposed 21,000 · Balance 0 F3: Represents the payment per share received in exchange for the cancellation of each option of $25.50, less the applicable exercise price. F1: In connection with the acquisition by Tungsten Bidco Limited of the entire issued and to be issued share capital of Nightstar Therapeutics plc (the "Issuer") on June 7, 2019 by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006, all stock options were cancelled in exchange for a payment equal to $25.50 with respect to each ordinary share subject to the option award, less the applicable exercise price. F2: The ordinary shares, nominal value GBP 0.01 per share, of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the acquisition by Tungsten Bidco Limited of the entire issued and to be issued share capital of Nightstar Therapeutics plc (the "Issuer") on June 7, 2019 by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006, all stock options were cancelled in exchange for a payment equal to $25.50 with respect to each ordinary share subject to the option award, less the applicable exercise price.
F2: The ordinary shares, nominal value GBP 0.01 per share, of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer.
F3: Represents the payment per share received in exchange for the cancellation of each option of $25.50, less the applicable exercise price.
PROTHENA CORP PUBLIC LTD CO
Report date May 14, 2025 · Filed May 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.89 · Expires 2035-05-14 | Direct | 20,183 |
Reported balance
After 2025-05-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-14 · Grant · Acquired 20,183 · Balance 20,183 F1: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2026 of the Issuer's shareholders, assuming continuous service as a director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2026 of the Issuer's shareholders, assuming continuous service as a director until such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 14, 2025 Filed May 16, 2025 20:44 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 20,183 | $0.00 Strike: $6.89 | $0.00 |
DisclosureSEC source: 0000905148-25-001826 · form4.xml · derivative · entry 1 Cobb Paula K · CIK 0001763372 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,183 Underlying: Ordinary Shares · 20,183 shares Expires 2035-05-14 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2026 of the Issuer's shareholders, assuming continuous service as a director until such vesting date. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:29 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $22.39 | $0.00 |
DisclosureSEC source: 0000905148-24-001528 · form4.xml · derivative · entry 1 Cobb Paula K · CIK 0001763372 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Ordinary Shares · 15,000 shares Expires 2034-05-15 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2025 of the Issuer's shareholders, assuming continuous service as a director until such vesting date. Read SEC document |
| May 17, 2023 Filed May 20, 2023 01:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $76.00 | $0.00 |
DisclosureSEC source: 0001140361-23-025831 · form4.xml · derivative · entry 1 Cobb Paula K · CIK 0001763372 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Ordinary Shares · 15,000 shares Expires 2033-05-17 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2024 of the Issuer's shareholders, assuming continuous service as a director until such vesting date. Read SEC document |
| May 18, 2022 Filed May 28, 2022 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $25.60 | $0.00 |
DisclosureSEC source: 0001140361-22-021108 · form4.xml · derivative · entry 1 Cobb Paula K · CIK 0001763372 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Ordinary Shares · 15,000 shares Expires 2032-05-18 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2023 of the Issuer's shareholders, assuming continuous service as a director until such vesting date. Read SEC document |
| May 19, 2021 Filed May 21, 2021 21:04 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $23.97 | $0.00 |
DisclosureSEC source: 0001567619-21-010957 · doc1.xml · derivative · entry 1 Cobb Paula K · CIK 0001763372 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Ordinary Shares · 15,000 shares Expires 2031-05-19 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2022 of the Issuer's shareholders, assuming continuous service as a director until such vesting date. Read SEC document |
| May 20, 2020 Filed May 22, 2020 20:42 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $11.33 | $0.00 |
DisclosureSEC source: 0001567619-20-011041 · doc1.xml · derivative · entry 1 Cobb Paula K · CIK 0001763372 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Ordinary Shares · 17,500 shares Expires 2030-05-20 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2021 of the Issuer's shareholders, assuming continuous service as a director until such vesting date. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 18:11 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $10.02 | $0.00 |
DisclosureSEC source: 0001567619-19-014389 · doc1.xml · derivative · entry 1 Cobb Paula K · CIK 0001763372 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Ordinary Shares · 35,000 shares Expires 2029-07-02 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 33 1/3% of the total number of shares subject to the option on the first anniversary of the grant date, 33 1/3% on the second anniversary of the grant date, and the remaining 33 1/3% on the earlier of the third anniversary of the grant date or the day prior to the annual general meeting in 2022 of the Issuer's shareholders, assuming continuous services as a director until each such vesting date. Read SEC document |
| June 07, 2019 Filed Jun 7, 2019 16:32 UTC | Nightstar Therapeutics plc NITE · Entity 156809 | Disposition to issuerStock Option (Right to Buy) · Derivative | 21,000 | $11.93 Strike: $13.57 | $250,530.00 |
DisclosureSEC source: 0001209191-19-035551 · doc4.xml · derivative · entry 2 Cobb Paula K · CIK 0001763372 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 21,000 shares Expires 2029-01-24 F3 · price: Represents the payment per share received in exchange for the cancellation of each option of $25.50, less the applicable exercise price. F1 · derivative.exercise_date: In connection with the acquisition by Tungsten Bidco Limited of the entire issued and to be issued share capital of Nightstar Therapeutics plc (the "Issuer") on June 7, 2019 by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006, all stock options were cancelled in exchange for a payment equal to $25.50 with respect to each ordinary share subject to the option award, less the applicable exercise price. F2 · derivative.underlying: The ordinary shares, nominal value GBP 0.01 per share, of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. Read SEC document |
| June 07, 2019 Filed Jun 7, 2019 16:32 UTC | Nightstar Therapeutics plc NITE · Entity 156809 | Disposition to issuerStock Option (Right to Buy) · Derivative | 36,400 | $0.34 Strike: $25.16 | $12,376.00 |
DisclosureSEC source: 0001209191-19-035551 · doc4.xml · derivative · entry 1 Cobb Paula K · CIK 0001763372 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 36,400 shares Expires 2028-09-11 F3 · price: Represents the payment per share received in exchange for the cancellation of each option of $25.50, less the applicable exercise price. F1 · derivative.exercise_date: In connection with the acquisition by Tungsten Bidco Limited of the entire issued and to be issued share capital of Nightstar Therapeutics plc (the "Issuer") on June 7, 2019 by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006, all stock options were cancelled in exchange for a payment equal to $25.50 with respect to each ordinary share subject to the option award, less the applicable exercise price. F2 · derivative.underlying: The ordinary shares, nominal value GBP 0.01 per share, of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 21:00 UTC | Nightstar Therapeutics plc NITE · Entity 156809 | GrantStock Option (Right to Buy) · Derivative | 21,000 | $0.00 Strike: $13.57 | $0.00 |
DisclosureSEC source: 0001209191-19-005960 · doc4.xml · derivative · entry 1 Cobb Paula K · CIK 0001763372 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Ordinary Shares · 21,000 shares Expires 2029-01-24 F1 · derivative.exercise_date: This option vests in full on the close of business the day before the 2020 Annual General Meeting of Shareholders. F2 · derivative.underlying: The ordinary shares, nominal value GBP 0.01 per share, of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.